Nkarta presents NKX101 clinical data at 2023 ASH Annual Meeting

Nkarta announced a poster presentation at the 2023 American Society of Hematology Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory acute myeloid leukemia. NKX101 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target NKG2D ligands. As reported in June 2023, of those patients who received NKX101 after a disease-specific lymphodepletion regimen comprising fludarabine and cytarabine, four of six achieved CR/CRi. In the follow up presented today, three of those four patients remained in CR/CRi at 4 months from treatment with NKX101. No cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease of any grade were observed in these patients. Nkarta plans to provide an update from the NKX101 Flu/Ara-C LD cohort in the first half of 2024 that includes preliminary safety and response data from 12 to 20 additional patients.